Table 5. Survival analysis of patients in the training set and validation set in terms of TsNL staging system.
| Training set (n= 510) | Validation set (n= 509) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stage | 1-yr OS | 3-yr OS | 5-yr OS | MS (month) | 1-yr OS | 3-yr OS | 5-yr OS | MS(month) | ||
| I | 94.6% | 91.8% | 86.1% | 107.0(1.8-170.0) | 95.1% | 90.3% | 87.8% | 94.3(1.5-173.3) | ||
| II | 93.4% | 88.9% | 75.2% | 98.2(0.9-172.1) | 94.1% | 86.6% | 72.4% | 87.0(1.9-173.1) | ||
| III | 93.3% | 80.5% | 66.4% | 72.9(2.5-170.8) | 93.9% | 82.1% | 61.6% | 68.0(3.2-171.8) | ||
| IV | 92.5% | 72.2% | 48.1% | 72.8(1.2-172.0) | 93.1% | 74.6% | 54.1% | 65.4(1.4-169.0) | ||
| V | 88.6% | 60.4% | 40.3% | 40.4(0.7-146.0) | 89.9% | 63.0% | 43.9% | 45.2(0.9-134.2) | ||
OS: overall survival; MS: median survival time.